30/07/2025
In a striking breakthrough, researchers discovered that melittin — the primary active compound in bee venom — can selectively target and kill aggressive breast cancer cells in laboratory (in vitro) settings. In a 2020 study conducted by the Harry Perkins Institute of Medical Research in Australia, melittin was shown to destroy triple-negative and HER2-enriched breast cancer cells within 60 minutes, while sparing healthy cells. The compound appears to punch holes in cancer cell membranes and block key signaling pathways, stopping tumor growth in its tracks.
However, this exciting discovery is still in its early stages. These effects have only been demonstrated in cell cultures, and much more research is needed to determine if melittin can be safely and effectively used in human cancer treatments. Scientists are now exploring how to harness its power through targeted delivery systems to avoid toxicity. If successful, this natural venom component could one day become a powerful tool in the fight against some of the most treatment-resistant forms of cancer.